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Anti-anhedonic effect of ketamine and its neural correlates in
treatment-resistant bipolar depression
N Lally1,2, AC Nugent1, DA Luckenbaugh1, R Ameli1, JP Roiser2 and CA Zarate1
Anhedonia—which is deﬁned as diminished pleasure from, or interest in, previously rewarding activities—is one of two cardinal
symptoms of a major depressive episode. However, evidence suggests that standard treatments for depression do little to alleviate
the symptoms of anhedonia and may cause reward blunting. Indeed, no therapeutics are currently approved for the treatment of
anhedonia. Notably, over half of patients diagnosed with bipolar disorder experience signiﬁcant levels of anhedonia during a
depressive episode. Recent research into novel and rapid-acting therapeutics for depression, particularly the noncompetitive N-
Methyl-D-aspartate receptor antagonist ketamine, has highlighted the role of the glutamatergic system in the treatment of
depression; however, it is unknown whether ketamine speciﬁcally improves anhedonic symptoms. The present study used a
randomized, placebo-controlled, double-blind crossover design to examine whether a single ketamine infusion could reduce
anhedonia levels in 36 patients with treatment-resistant bipolar depression. The study also used positron emission tomography
imaging in a subset of patients to explore the neurobiological mechanisms underpinning ketamine’s anti-anhedonic effects. We
found that ketamine rapidly reduced the levels of anhedonia. Furthermore, this reduction occurred independently from reductions
in general depressive symptoms. Anti-anhedonic effects were speciﬁcally related to increased glucose metabolism in the dorsal
anterior cingulate cortex and putamen. Our study emphasizes the importance of the glutamatergic system in treatment-refractory
bipolar depression, particularly in the treatment of symptoms such as anhedonia.
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INTRODUCTION
Over half of patients diagnosed with bipolar disorder (BD) suffer
from signiﬁcant levels of anhedonia,1 deﬁned as loss of enjoyment
in, or desire to engage in, previously pleasurable activities.2
Notably, anhedonic patients with affective disorders have a poorer
treatment prognosis than their non-anhedonic counterparts.3–5
Indeed, accumulating evidence suggests that standard treatments
for depression do little to alleviate anhedonia6 and may even
cause reward and emotional blunting,7–9 sexual anhedonia10 and
anorgasmia.11,12 Furthermore, the presence of anhedonia in a
major depressive episode (MDE) is a predictor of proximal suicide
completion.13 Critically, no US Food and Drug Administration-
approved treatment currently exists speciﬁcally for anhedonia.
The Diagnostic and Statistical Manual-5 (ref. 14) identiﬁes
anhedonia as one of two cardinal symptoms in the diagnosis of an
MDE in both major depressive disorder (MDD) and BD. Anhedonia
can be subdivided into consummatory (subjective pleasure, for
example, enjoying food) and motivational components (anticipa-
tion of and drive towards rewarding stimuli, for example, planning
and looking forward to a vacation) that have distinct biological
bases.15
Indeed, research suggests that currently depressed MDD and
BD patients may possess a substantial deﬁcit in motivational, but
not consummatory, reward behaviors.16,17 Studies using the sweet
taste test—a task that mirrors preclinical assessments of
consummatory anhedonia in rodents—found that patients with
MDD demonstrated the same preference for sucrose water
concentrations as healthy volunteers.18,19 Furthermore, Sherdell
et al.20 found that MDD patients experienced the same levels of
pleasure as healthy volunteers while viewing humorous cartoons
in a computer task, but were not willing to exert as much effort to
gain access to these stimuli; the results suggest intact consum-
matory processes, but attenuated motivational ones. In another
study, Etain et al.21 found no evidence for consummatory
anhedonia in BD patients. Although research pertaining to BD
patients in particular is lacking, overall, the extant evidence
suggests that anhedonia in depression is primarily associated with
a deﬁcit in non-consummatory reward behaviors. Understanding
the neural pathways that mediate anticipatory pleasure is thus a
critical step towards successful treatment of anhedonia.
Dopaminergic signaling has been consistently correlated with
the anticipation, motivation and learning related to pleasurable
stimuli, but not to their consumption.22–24 Phasic bursts in
dopaminergic neurons in the ventral tegmental area (VTA) have
reliably been shown to co-occur with violations in reward
expectancy,25 underscoring the evidence for dopaminergic
signalling in reward learning. Furthermore, dopamine signalling
in the nucleus accumbens, an area of dense dopaminergic
projections from the VTA, has been strongly associated with
reward motivation in rodents.26 Functional neuroimaging in
humans indicates that structures such as the VTA,27,28 substantia
nigra,28 amygdala,28 putamen,28 caudate,28 ventral striatum,29,30
and orbitofrontal cortex28,31—all of which receive innervation
from or project to dopaminergic nuclei—are recruited during
reward anticipation.
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Despite the abnormalities in motivational behaviors seen in
affective disorders, there is a dearth of robust evidence pertaining
to any direct dopaminergic signaling deﬁcit in patients with
depression.32 The strongest indirect evidence for dopaminergic
dysfunction in depression comes from pharmacological treatment
studies. For instance, the dopamine D2 receptor agonist
pramipexole improved levels of depression in both MDD33 and
BD34,35 patients after several weeks of daily administration. A
study of Parkinson’s disease patients with co-occurring depression
used the Snaith–Hamilton Pleasure Scale (SHAPS36), and found
that pramipexole treatment decreased anticipatory anhedonia
levels by 25% across the entire sample;37 however, it is unknown
whether this reduction occurred as a function of improvement in
mood, Parkinson’s symptomatology or hedonic capacity.
It is presently unclear whether anhedonic symptoms in
depression improve faster with dopaminergic-enhancing medica-
tions than with standard treatments. Furthermore, because
improvements in self-reported levels of anhedonia are reportedly
the last symptom to improve with selective serotonin reuptake
inhibitors,38 there is a critical unmet need for rapid-acting
treatments for anhedonia. The fact that standard antidepressants
lack any proven anti-anhedonic efﬁcacy, particularly in conjunc-
tion with the deleterious side effects associated with these agents,
requires novel pharmacotherapeutic approaches.
The noncompetitive N-Methyl-D-aspartate (NMDA) receptor
antagonist ketamine has shown remarkable consistency in rapidly
ameliorating depressive symptoms in both MDD39–43 and BD.44,45
However, it is unknown whether ketamine also possesses any
speciﬁc anti-anhedonic efﬁcacy. Given the likely mechanistic
heterogeneity of depression, it is critical to understand the
speciﬁc targets of treatment response at both the clinical and
neural levels, as outlined in the research domain criteria.46
Ketamine acts directly on the glutamatergic system, which
appears to be critical in depression;47,48 however, little is known
about the speciﬁcity of the relationship between commonly
occurring symptoms during an MDE (for instance, anhedonia,
anxiety) and particular biological phenotypes. In a small sample
investigation, Walter et al.49 found that MDD patients with high
levels of anhedonia had lower levels of glutamine, but not
glutamate, than healthy controls, but only a trend towards lower
glutamine than MDD patients with low levels of anhedonia, who
did not differ from controls. Preclinical evidence suggests that
blockade of astrocytic glutamate reuptake in rodents can induce
anhedonia-like behaviors,50 particularly in the prefrontal cortex.51
In addition, ketamine52,53 and other NMDA antagonists (for
example, MK-80154 and memantine55) have been shown to
reverse anhedonic phenotypes in rodents. However, preclinical
evidence typically classiﬁes anhedonia as a decrease in con-
summatory behavior; although anticipatory and consummatory
behaviors likely interact, extrapolating from rodent behaviors to
clinical patient symptoms is not straightforward. Sub-anesthetic
doses of ketamine acutely increase glutamatergic and dopami-
nergic signaling in the prefrontal cortex of rats.56 Given the
apparent role of dopaminergic and glutamatergic signaling in
mediating anhedonia and the reported pharmacological effects in
both rodents and humans, ketamine may be ideally suited to
speciﬁcally ameliorate anticipatory anhedonia in currently
depressed patients.
This randomized, double-blind, placebo-controlled, crossover
study assessed the anti-anhedonic efﬁcacy of ketamine in
treatment-resistant BD patients currently experiencing an MDE.
Regional neural metabolism following both placebo and ketamine
infusions were also measured in a subsample of these patients
using [18F] ﬂuorodeoxyglucose (FDG) positron emission tomogra-
phy (PET). 18FDG-PET measures glucose metabolism, which is
primarily determined by glial uptake of glucose in response to
glutamate release from neurons, and principally reﬂects glutama-
tergic neurotransmitter release and cycling.57 It is important to
note that approximately all glucose entering the central nervous
system is transformed into glutamate.58 Thus, 18FDG-PET provides
an indirect quantitative measure of cerebral glutamate metabo-
lism throughout the entire brain. The effects of ketamine on
general depressive symptoms in the majority of BD subjects
presented here (33/36, 92%) were previously reported,44,45
together with neurobiological correlates of mood improvement
derived from 18FDG-PET.59 The present study speciﬁcally explores
the previously unaddressed issue of ketamine’s anti-anhedonic
effects and its neural correlates in this sample.
MATERIALS AND METHODS
Participants
Subjects aged 18–65 were recruited through local and national media. The
sample comprised 36 (21F) treatment-refractory individuals with BD I or II
without psychotic features who were currently experiencing an MDE (see
Table 1). All subjects were inpatients at the National Institutes of Health
(NIH), Bethesda, MD, USA. A Montgomery–Åsberg Depression Rating Scale
(MADRS)60 score ⩾ 20 at the time of screening was an inclusion criterion.
All subjects were required to be currently experiencing an MDE lasting at
least 4 weeks and to have failed to respond to at least one adequate
antidepressant trial before hospital admission, as assessed by the
Antidepressant Treatment History Form.61 Diagnosis was conﬁrmed using
the Structured Clinical Interview for Axis I Diagnostic and Statistical
Manual-IV Disorders-Patient Version.62 Primary psychiatric categorization,
including comorbid Axis I disorders, was corroborated via evaluation by
three clinicians using all available clinical information. During their time as
inpatients at the NIH, and before study entry, participants had also not
responded to a prospective open-label trial of a mood stabilizer (either
lithium or valproic acid) administered at treatment levels (serum lithium,
0.6–1.2 mEq l− 1; or valproic acid, 50–125 μgml− 1).
All patients were in good physical health as determined by medical
examination, medical history, chest x-ray, blood laboratory tests, urinary
analysis and toxicology. Exclusion criteria, as outlined previously,44,45
included pregnancy, nursing, serious suicidal ideation, comorbid substance
abuse or dependence within the past 3 months, and previous use or
treatment with ketamine. The co-occurrence of Axis I anxiety disorders was
permitted if this was not the primary cause of illness within the previous
12-month period. All participants continued treatment with a mood
Table 1. Demographic information for BD patients and the subgroup






Mean s.d. Mean s.d.
Age 46.69 11.09 45.33 11.89
Age of onset 17.89 7.39 17.50 7.49
Baseline SHAPS 37.19 7.25 36.14 7.92
Baseline MADRS 33.92 5.01 30.05 4.89
BMI 30.09 6.04 29.08 6.34
N % N %
Bipolar subtype I 20 55 9 43
Caucasian 31 86 18 86
Clinically sig. anhedonia36 31 86 17 81
Female 21 58 15 71
Fhx alcohol dependence (1st) 13 36 8 38
Fhx mood disorder 31 86 17 81
Lithium 24 67 16 76
Abbreviations: BD, bipolar disorder; BMI, body mass index; 18FDG-PET, [18F]
ﬂuorodeoxyglucose-positron emission tomography; Fhx, family history;
MADRS, Montgomery–Åsberg Depression Rating Scale; SHAPS, Snaith–
Hamilton Pleasure Scale. Clinically signiﬁcant (sig.) anhedonia was deﬁned
as scoring three or more items on the SHAPS with a value of 3 (‘Disagree’),
as per the original classiﬁcation by Snaith et al.36
Anti-anhedonic effect of ketamine in BD
N Lally et al
2
Translational Psychiatry (2014), 1 – 9 © 2014 Macmillan Publishers Limited
stabilizer (either lithium or valproic acid) administered at therapeutic levels
during the course of the study, although this was not adequate to alleviate
depressive symptoms. Aside from monotherapy with a mood stabilizer, no
psychotropic medication or psychotherapy was permitted in the 2 weeks
before study randomization (5 weeks for ﬂuoxetine) or during the 4-week
study period. Written informed consent was obtained from all participants,
and the NIH Combined Neuroscience Institute Review Board approved
the study.
Design
The study was designed as a randomized, double-blind, placebo-
controlled, crossover study to assess the antidepressant efﬁcacy of
ketamine in patients with treatment-refractory BD. All participants received
one intravenous infusion of ketamine hydrochloride, administered at a
subanesthetic dose of 0.5 mg kg− 1, and one infusion of placebo (0.9%
saline solution) in a randomized order over a 4-week study period, and
with 2 weeks between each infusion. A MADRS score ⩾ 20 on the morning
of each infusion was required for study continuation. An anesthesiologist
administered each infusion over 40min using a Baxter infusion pump
(Deerﬁeld, IL, USA). The two solutions and the appearance of the drug
syringe were identical and all study team members were blind to the drug
condition.
Clinical ratings were acquired 60min before the infusion and thereafter
at 40, 80, 120, 230min, and days 1, 2, 3, 7, 10 and 14 following each
infusion. The primary outcome variable for antidepressant efﬁcacy was the
MADRS44,45 score. However, the main symptom of interest for this report is
anhedonia, and levels of anticipatory anhedonia were evaluated using the
SHAPS. The SHAPS is a 14-item, self-administered, user friendly and state-
sensitive psychometric scale that overcomes limitations associated with
other scales that speciﬁcally assess anhedonia, such as length and cultural
idiosyncrasies. Importantly, the SHAPS has been validated in a number of
independent samples since its publication.63–65 The SHAPS was scored on
a scale of one to four, with higher scores indicating greater anhedonia
(range 14–56) and was administered with reference to either the past 24 h
or the time between the present and the previous rating. The presence or
absence of anhedonia was judged on the basis of the original scoring
guidelines (range 0–14),36 where a score43 indicated clinically signiﬁcant
anhedonia (see Table 1). Other secondary outcome variables were also
assessed and have been reported previously.44,45
Positron emission tomography acquisition and analysis
In addition, 21 of the 36 patients (see Table 1) underwent two resting-state
18FDG-PET imaging scans, which began 2 h post infusion and ended (brain
emission scan) ~ 1.5 h later. Immediately before both scans, patients
completed psychometric rating scales; identical procedures were followed
for both scans. PET imaging was performed on a GE Advance PET scanner
(GE Medical Systems, Waukesha, WI, USA) in three-dimensional mode (35
contiguous slices, 4.25mm plane separation) following an intravenous
infusion of 4.5 mCi 18FDG over 2 min. According to the method used by
Brooks,66 quantitative images of regional cerebral metabolic rate for
glucose metabolism (rCMRGlu) were calculated using a cardiac input
function derived from a dynamic left ventricular scan collected before both
the brain emission scan and venous sampling (reconstructed resolution= 6
mm full-width at half-maximum in all planes). Magnetic resonance
imaging (MRI) images were acquired on a 3-Tesla scanner (Signa, GE
Medical Systems) using a three-dimensional MPRAGE sequence (echo
time= 2.982ms, repetition time=7.5 ms, inversion time=725ms, voxel
size = 0.9 × 0.9 × 1.2 mm) to allow anatomic localization of PET activity. PET
analyses comprised both a region of interest approach (ROI) and a whole-
brain investigation.
The ROI analysis pipeline used here has been previously described.59
Brieﬂy, the Analysis of Functional NeuroImages (AFNI; Bethesda, MD, USA)
function 3dSkullStrip was used to remove non-brain tissue from the
anatomical MRI image. These images were segmented into gray and white
matter, and cerebrospinal ﬂuid (separate binary mask images were
computed for each component) using the FSL (Oxford, UK) automated
segmentation tool. Anatomical images were spatially normalized to the
Montreal Neurological Institute 152 template. ROIs (ventral striatum and
orbitofrontal cortex) were selected on the basis of extant literature
implicating these neuroanatomical structures in depression67–70 and
reward anticipation.16,31 The ventral striatum ROI comprised only the
nucleus accumbens and olfactory tubercle. Template-deﬁned ROIs were
transferred to the individual anatomical MRIs; to accommodate
interindividual anatomical variation, ROI placement was adjusted per
subject. ROIs were transferred back to the native MRI space, multiplied by a
binary gray matter mask and applied to the rCMRGlu PET images. Mean
glucose metabolism rate values, normalized by total gray matter, were
then calculated.
For the whole-brain investigation, 18FDG-PET images were preprocessed
and analyzed using Statistical Parametric Mapping software (SPM;
Wellcome Trust Centre for Neuroimaging, London, UK) version 5 within
the MATLAB (MathWorks, Natick, MA, USA) environment. Post-placebo and
post-ketamine rCMRGlu images were separately co-registered to the
anatomical image; the anatomical image was then normalized to Montreal
Neurological Institute space and this transformation was applied to the co-
registered PET images. A Gaussian smoothing kernel (8 mm full-width at
half-maximum) was applied to the PET images. To create difference images
for each individual, PET images were ﬁrst normalized by the global mean
(as calculated in SPM) and the post-placebo image was subtracted from
the post-ketamine image. A binary mask was applied to all whole-brain
investigations to limit the number of multiple comparisons to only
intracerebral voxels.
Statistical analyses
Symptom rating scale analysis included all available data and was
conducted using IBM SPSS (Armonk, NY, USA; version 21). Linear mixed
models, using a heterogeneous ﬁrst-order autoregressive covariance
structure and restricted maximum-likelihood estimation, were performed
to assess the effects of ketamine versus placebo on SHAPS scores over the
4-week period in this crossover design. Fixed main effects of time and drug
and their interaction were included along with a random effect for subject.
To correct for baseline levels of anhedonia, the SHAPS score at baseline on
each infusion day (time point − 60) was entered as a covariate into the
model. In addition, a linear mixed model with total MADRS score (at each
individual time point) entered as a covariate was conducted to evaluate
whether ketamine infusion was associated with a change in SHAPS score
independent of the effect on other depressive symptoms. MADRS item 8
(inability to feel) was removed from the total MADRS score for this analysis
due to the strong conceptual overlap between this item and the SHAPS.
Post hoc Bonferonni-corrected comparisons were conducted for each
model for all post-baseline time points to determine the speciﬁc timing of
the anti-anhedonic effects. All signiﬁcance values were two-tailed, with a
signiﬁcance threshold of Po0.05.
The time point of 230min was a priori selected for both the ROI and
whole-brain analyses on the basis of three factors: previous studies
indicating that 230min is a sensitive time point for detecting antidepres-
sant effects of ketamine;44,45 lack of psychotomimetic effects at this time
point; and the proximity to the time of the PET scan. Relationships
between glucose metabolism in our ROIs (post-placebo and post-ketamine
and their difference) and SHAPS score were investigated using Pearson
product moment correlation coefﬁcients. First, percentage improvement in
SHAPS score at 230min post infusion ((post-ketamine 230−post-placebo
230)/post-placebo 230) was correlated with difference in mean ROI
rCMRGlu metabolism (post-ketamine–post-placebo). Second, because we
previously demonstrated an association between ventral striatum meta-
bolism changes and overall depression score change following ketamine,59
we conducted a multiple linear regression analysis to parse the variance
associated with anhedonia and total depression score and explore which
variable predicted change in ventral striatum metabolism. Finally, as a
control analysis, we also assessed whether state-dependent anhedonia
levels, as measured by raw SHAPS score, were associated with ROI
rCMRGlu, both variables post-ketamine and post-placebo.
Complementing the ROI analysis, the whole-brain investigation com-
prised the following multiple regression analyses. First, percent improve-
ment on the SHAPS at 230min (as above) was regressed onto the
difference images (post-placebo–post-ketamine). Second, to assess the
speciﬁcity of the results to anhedonia, and not depressive symptoms
per se, we recomputed the whole-brain analyses with percentage change
anhedonia scores orthogonalized to the corresponding percentage change
in MADRS score (minus item 8) using the SPM spm_orth function within the
MATLAB environment, entering a single regressor (SHAPS score orthogo-
nalized to total MADRS score minus item 8). Orthogonalization of one
variable against another, in this instance the SHAPS against the MADRS
score, results in the removal of shared variance; the output variable
represents the residual SHAPS score when the variance associated with the
MADRS has been accounted for. Here, we report only those analyses that
survived stringent Gaussian random ﬁeld theory cluster correction for
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multiple comparisons at Po0.05, or at trend level at Po0.1, with an initial
voxel-level threshold of Po0.05 uncorrected. In the case of extremely
large clusters, the uncorrected threshold was increased so that all surviving
clusters were o5000 contiguous voxels. For clusters surviving correction
or trending, the three strongest peaks (t statistics) are reported along with
the corresponding Montreal Neurological Institute coordinates.
RESULTS
Subjects
Patient demographic details are presented in Table 1. One patient
was excluded from the PET analyses due to a failure to measure
the cardiac input function, and another subject was excluded
because there was no SHAPS scale score measurement at 230min
post-ketamine and post-placebo infusions.
Behavioral response
Main effects of drug (F(1,110) = 24.71, Po0.001) and time
(F(9,194) = 2.69, P= 0.006) were observed, as was a trend towards
an interaction between these two variables (F(9,218) = 1.90,
P= 0.053); this indicates that ketamine caused a greater reduction
in levels of anhedonia across time than placebo, (Figure 1a).
Bonferonni-corrected post hoc comparisons demonstrated that
ketamine, compared with placebo, signiﬁcantly decreased levels
of anhedonia at multiple times throughout the 14-day period
following a single ketamine infusion (Figure 1a).
Consistent with previous reports,1 levels of anhedonia (as
measured by the SHAPS) and depressive symptoms (as measured
by total MADRS score) were positively correlated (r(36) = 0.53,
Po0.001) at the ﬁrst pre-infusion baseline. Critically, the main
effect of drug on anhedonia levels was found when levels of
depression (MADRS total score minus item 8 at each time point)
were entered as a covariate in the model (F(1,123) = 7.713, P
= 0.006), indicating that anhedonia levels in BD respond to
ketamine treatment over-and-above its effects on other depres-
sive symptoms. Neither the main effect of time (F(9,176) = 1.42,
P= 0.18) nor the drug-by-time interaction (F(9,219) = 1.49, P= 0.15)
were signiﬁcant for this model. However, post-hoc exploratory
simple effects tests (Bonferonni-corrected) revealed that anti-
anhedonic effects of ketamine were signiﬁcant at days 1, 3, 7 and
14 following ketamine infusion (Figure 1b). This suggests that for
some BD patients, ketamine may have speciﬁc beneﬁts in
reducing anhedonia levels, and that these beneﬁts can last up
to 2 weeks following a single infusion.
A subsequent model included mood stabilizer as an additional
covariate; a trend towards signiﬁcance, with greater anti-
anhedonic response associated with lithium than valproate was
observed (F(1,57) = 3.57, P= 0.06). No interaction effect was noted
between drug (ketamine or placebo) and mood stabilizer (F(1,
114) = 0.08, P= 0.78), nor was there a three-way interaction
between drug, mood stabilizer and time (F(9, 225) = 0.41, P= 0.93).
Given our previous ﬁndings that a positive family history of
alcohol use disorder (1st degree relative) was associated with an
enhanced response to ketamine,71,72 we examined whether this
factor was also associated with the speciﬁc anti-anhedonic
response demonstrated above; baseline SHAPS score and total
depression score were entered as covariates into a subsequent
model. There was a signiﬁcant interaction between drug and
family history of alcohol use disorder (F(1,109) = 4.12, P= 0.045), but
no main effect for family history of alcohol use disorder
(F(1,51) = 0.27, P= 0.60), nor an interaction between this variable
and time (F(9,163) = 0.94, P= 0.49), nor a three-way interaction
between family history, drug and time (F(9,205) = 0.60, P= 0.79). The
signiﬁcant interaction between drug and family history of an
alcohol use disorder indicated, in comparison with placebo, a
speciﬁc enhanced anti-anhedonic response to ketamine in those
with (F(1,116) = 11.13, P = 0.001), in comparison with those without
(F(1,111) = 1.22, P = 0.27), a family history of an alcohol use disorder.
In addition, we explored whether a personal history of alcohol
abuse, dependence or illicit substance abuse contributed sig-
niﬁcantly to the speciﬁc anti-anhedonic effect of ketamine. No
signiﬁcant main effects or interactions with drug, time or drug and
time were found.
PET: ROI analyses
Ketamine-induced change in ventral striatum rCMRGlu was
signiﬁcantly related to percent change in SHAPS score at
230min post infusion (r(19) =− 0.52, P= 0.02; Figure 1c). Relative
to placebo, individuals with the largest increase in glucose
metabolism in the ventral striatum tended to have the highest
anti-anhedonic response to ketamine. However, orbitofrontal
cortex rCMRGlu activity was not signiﬁcantly related to anti-
anhedonic response to ketamine (r(19) =− 0.37, P= 0.12). Because
we had previously demonstrated a relationship between ventral
striatum change in glucose metabolism and improvement in
MADRS score following ketamine,59 we tested whether this
relationship was speciﬁc to anhedonia. Multiple regression,
including both SHAPS and MADRS (minus item 8), indicated that
change in MADRS (t=− 2.18, P= 0.045), but not SHAPS (t=− 0.05,
P= 0.96), signiﬁcantly predicted change in ventral striatum
rCMRGlu.
Examining each session separately, we found no signiﬁcant
correlations between absolute SHAPS scores and ventral striatum
or orbitofrontal cortex rCMRGlu, respectively, neither post placebo
(r(19) = 0.03, P= 0.91; r(19) = 0.10, P= 0.68) nor post ketamine
(r(20) = 0.06, P= 0.81; r(20) = 0.06, P= 0.81).
PET: Whole-brain analyses
Due to the presence of a large cluster, the statistical threshold was
raised to 0.025 uncorrected, as opposed to 0.05, for the initial
difference image contrast only. Whole-brain analyses revealed a
signiﬁcant relationship between percent improvement (decrease)
in SHAPS scores and rCMRGlu increases in the dorsal anterior
cingulate cortex (dACC; [x =− 6, y = 40, z = 43]; t(17) = 4.39, Pcorr =
0.016; Figure 1d). Furthermore, we found a signiﬁcant increase in
cerebellum ([x =− 40, y =− 48, z =− 58]; t(17) = 3.94, Pcorr = 0.019;
Table 2), and a trend towards an increase in striatal, rCMRGlu
([x = 14, y = 4, z = 10]; t(17) = 4.28, Pcorr = 0.051; Figure 1e), in relation
to the percent amelioration in SHAPS scores. Importantly, the
striatal cluster extended from the caudate to the putamen and
into the ventral striatum (Table 2), corroborating our ROI analysis.
The inverse contrast (the relationship between decreases in
rCMRGlu and change in SHAPS score) did not yield any whole-
brain corrected results.
Because our ROI results indicated that metabolic increases in
the ventral striatum appear to be driven by change in total
depression score but not levels of anhedonia, we conducted a
subsequent whole-brain analysis. In this model, change in SHAPS
score was orthogonalized to change in MADRS score, both at
230min, and this orthogonalized change in SHAPS score was
regressed onto the rCMRGlu difference image. This regression
revealed that the speciﬁc changes in anhedonia levels following
ketamine—which were not related to general changes in
depressive symptoms—were in fact associated with increased
dACC metabolism ([x =− 8, y = 40, z = 28]; t(17) = 4.89, Pcorr = 0.027;
Figure 1f) that extended into the pregenual cingulate/callosal
region and the right dorsolateral prefrontal cortex. In addition, a
trend was noted towards signiﬁcantly increased metabolism in the
fusiform gyrus ([x = 34, y =− 28, z =− 20]; t(17) = 3.74, Pcorr = 0.065)
that extended into the claustrum and the putamen, but not the
ventral striatum. Finally, we assessed whether change in rCMRGlu
was associated with longer-term SHAPS response by correlating
the difference in dACC (peak voxel; ketamine-placebo)
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Figure 1. Anti-anhedonic effect of ketamine and corresponding regression analyses with cerebral glucose metabolism. (a) Snaith–Hamilton
Pleasure Scale (SHAPS) estimated scores from linear mixed model 1 (M1) indicating a signiﬁcant reduction in anhedonia levels following
ketamine (red) compared with placebo (blue). (b) Model 2 (M2) is the same as model 1 (M1) but has total depression score (as assessed by the
Montgomery–Åsberg Depression Rating Scale (MADRS) minus item 8) entered as a covariate and still reveals a main effect of drug, thus
underscoring the unique anti-anhedonic effect of ketamine administration. Asterisks indicate Bonferonni-corrected comparisons at Po0.05
for both A and B. (c) Region of interest analysis with ventral striatum (VS) demonstrating a signiﬁcant association between anti-anhedonic
response to ketamine and increased glucose metabolism in the VS. Changes in anhedonia levels no longer signiﬁcantly predicted VS change
when change in overall depressive symptoms were controlled for. (d, e) Whole-brain corrected relationship between the anti-anhedonic
effects of ketamine and (d) dorsal anterior cingulate cortex (dACC), cerebellum, (e) right putamen, VS and medial posterior orbitofrontal cortex
increases in glucose metabolism. (f) Whole-brain corrected relationship between SHAPS score orthogonalized against MADRS score indicating
that a signiﬁcant increase in dACC metabolism was associated speciﬁcally with anti-anhedonic response to ketamine independent of overall
change in depressive symptoms. Error bars represent standard errors. PET images are presented (d and e, Po0.025 uncorrected; f, Po0.05
uncorrected) such that only clusters surviving family-wise error correction are shown. Color bars indicate positive t-values associated with
increasing glucose metabolism. ket, ketamine; pla, placebo; rCMRGlu, regional cerebral metabolic rate for glucose metabolism.
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metabolism with change in SHAPS scores at day 14. There was no
signiﬁcant relationship between change in dACC glucose meta-
bolism and the magnitude of the change in SHAPS score at day 14
(r(18) = 0.11, P= 0.66).
DISCUSSION
Several notable ﬁndings emerged from this study investigating
the effects of the rapid-acting antidepressant ketamine on
anhedonia in currently depressed treatment-resistant BD patients.
Foremost among these ﬁndings is that ketamine, compared with
placebo, rapidly reduced the levels of anhedonia in these patients;
this reduction occurred within 40min of a single ketamine
infusion and lasted up to 14 days. Furthermore, we found that
anti-anhedonic effects of ketamine remained signiﬁcant even
when controlling for level of depressive symptoms, suggesting
that ketamine has a unique role in ameliorating anhedonia levels
independent of other depressive symptoms. This study also used
18FDG-PET to examine a subgroup of these patients and quantify
the rCMRGlu correlates of change in anhedonia levels associated
with ketamine treatment. Our PET results demonstrated that the
neurobiology of this speciﬁc anti-anhedonic effect was mediated
in part by increases in glucose metabolism in the dACC, and
tentatively the putamen, but not the ventral striatum as originally
hypothesized.
These results are particularly important from a public health
perspective. No approved treatments for anhedonia currently exist
despite its prevalence across multiple psychiatric disorders. Thus,
ketamine’s rapid effects (within 1 h) on anhedonia levels are a
crucial clinical ﬁnding. Currently available standard treatments for
depression, such as selective serotonin reuptake inhibitors, have
few positive effects on levels of anhedonia in MDD patients and,
indeed, have occasionally deleterious effects;6–11,73 no research to
date has assessed the effects of mood stabilizers on levels of
anhedonia in individuals with BD. Our results lend credence to the
notion that similar compounds (for example, other NMDA receptor
antagonists) should be explored for their clinical relevance in
treating this debilitating symptom of depression. The results
further suggest that more typically anhedonic subtypes of
depression (both MDD and BD)—for instance, melancholic
depression—may be particularly suited to treatment with
ketamine and its analogs.
Given our previous ﬁnding59 that improvement in total
depression score on the MADRS was associated with increased
ventral striatum rCMRGlu following ketamine, we hypothesized
that this region would also be strongly related to anhedonia and
its amelioration. Unexpectedly, we found that ventral striatal
glucose metabolism was not associated with relative changes in
anhedonia levels after controlling for levels of depression. Possible
reasons for this result include the severity of illness in these
treatment-resistant BD subjects, the underlying biology of the
ventral striatum or the distinct symptom assessed by the SHAPS in
comparison with the MADRS. Alleviating depressive symptoms is
intensely relieving, and thus also rewarding, for treatment-
refractory patients. Intriguingly, opioid receptors in the medial
accumbens shell are believed to be solely responsible for ‘liking’ or
consummatory pleasure behaviors,74 whereas motivational hedo-
nic behaviors are thought to arise from a wide array of receptors
within the accumbens—the primary structure in the ventral
striatum—as well as other neural structures; 18FDG-PET cannot
currently differentiate these structures. Tentatively, we hypothe-
size that patients showing the greatest antidepressant response to
ketamine, as measured by the MADRS, may be experiencing high
levels of pleasure, a construct not assessed by the SHAPS. Further
investigations are needed to disentangle speciﬁc symptoms from
the systems level antidepressant mechanisms of action of
ketamine in humans.
However, our study did ﬁnd that individuals with the largest
increase in glucose metabolism (post-ketamine–post-placebo) in
the dACC and the putamen had the greatest clinical reduction in
anhedonia levels; notably, this was true with and without
controlling for total depression score. Findings from both human
and animal studies indicate that both the dACC and putamen are
highly involved in reward processing, learning and decision-
Table 2. 18FDG-PET imaging results
Region MNI coordinate t-value Uncorrected threshold PFWE− Corr PFDR− Corr Extent
X Y Z
Ketamine–Placebo vs SHAPS improvement
dACC − 6 40 30 4.39 Po0.025 0.014 0.016 2494
dACC 4 30 32 4.20
SMG − 2 50 42 3.82
Head of caudate 14 4 10 4.28 0.051 0.030 1936
Putamen 20 14 − 8 4.20
VS/posteromedial OFC 14 14 − 14 4.17
Cerebellum lobule VIIb − 40 − 48 − 58 3.94 0.019 0.016 2370
Cerebellum lobule III − 4 − 46 − 26 3.66
Cerebellum lobule VIIIA − 12 − 68 − 44 3.53
Ketamine–Placebo vs SHAPS orthogonalized to MADRS improvement
dACC − 8 40 28 4.89 Po0.05 0.027 0.042 4686
Pregenual/callosal cingulate − 6 34 8 3.62
DLPFC 30 40 36 3.18
Fusiform gyrus 34 − 28 − 20 3.74 0.065 0.052 3896
Claustrum 34 8 − 6 3.51
Putamen 22 14 −6 3.48
Abbreviations: dACC, dorsal anterior cingulate cortex; DLPFC, dorsolateral prefrontal cortex; 18FDG-PET, [18F] ﬂuorodeoxyglucose-positron emission
tomography; MADRS, Montgomery–Åsberg Depression Rating Scale; SHAPS, Snaith–Hamilton Pleasure Scale; SMG, superior medial gyrus. Increases in glucose
metabolism associated with decreases in anhedonia levels. All cluster P-values are corrected for multiple comparisons using Gaussian random ﬁeld theory as
implemented in SPM5. The three most signiﬁcant sub-peaks are given for each cluster. Montreal Neurological Institute (MNI) coordinates indicate the distance
(in millimeters) from the stereotaxic origin (anterior commissure), with x representing the lateral distance from the origin (positive numbers to the right), y
representing the anterior–posterior dimension (positive numbers anterior) and z representing the dorsal–ventral dimension (positive numbers dorsal).
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making.75–78 Shidara and Richmond75 demonstrated that reward
expectancy, or motivation, was highly correlated with single
neuron signals in the monkey ACC (area 24c), a proximal region to
the dACC rCMRGlu changes found here. Intriguingly, the dACC has
also been strongly linked with the anticipation of rewarding
events in humans.79 The dACC rCMRGlu increases seen in the
present study may reﬂect changes in the motivation and
anticipation of, or ability to anticipate, pleasurable events; this is
reﬂected in items of the SHAPS (‘I would enjoy a…’). Deﬁcits in the
ability to imagine future events, particularly positive ones, have
been reliably identiﬁed in MDD patients experiencing an MDE;80,81
thus, attenuation of depressive symptoms may be accompanied
by an improved ability to anticipate pleasure. In a functional MRI
study in humans, O’Doherty et al.28 found that anticipating a
primary reward (glucose) elicited heightened activity in the right
putamen (as found here) compared with anticipating a punish-
ment (salt water). Keedwell et al.82 found that anhedonia levels, as
measured by the Fawcett–Clark Pleasure Scale,83 were positively
correlated with activity in the right putamen during an emotional
face-processing task that required MDD patients to compare sad
and neutral faces; this result was not observed with depression or
anxiety scales, though it should be noted that the Fawcett–Clark
Pleasure Scale indiscriminately measures both consummatory and
anticipatory anhedonia. Taken together, the results of the imaging
portion of this study indicate that decreased anticipatory
anhedonia is associated with increased glucose metabolism in
the dACC and putamen, and that this in turn may reﬂect increased
motivation towards or ability to anticipate pleasurable
experiences.
Another interesting ﬁnding was that, after the ketamine
infusion, individuals taking lithium experienced greater anti-
anhedonic effects than those receiving valproate when the
antidepressant effect was controlled for. This result could be
interpreted in two ways: either valproate caused a deﬁcit in the
anti-anhedonic effect of ketamine, or lithium enhanced the anti-
anhedonic effect of ketamine. A recent preclinical report by Liu
et al.84 found that a single subanesthetic dose of ketamine in
conjunction with lithium resulted in enhanced plasticity and
antidepressant-like effects (increased struggling time in the forced
swim test) in rodents compared with a single dose of ketamine
plus vehicle. In light of this result, we suggest that lithium may
enhance the anti-anhedonic effects of ketamine in individuals
with BD. Future studies in patients both taking and not taking
mood stabilizers will need to be conducted to correctly evaluate
this possibility.
Ketamine acts primarily by blocking the glutamatergic NMDA
receptor. It may also upregulate α-Amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor throughput.85 Although gluta-
mate is the major excitatory neurotransmitter, its role in
anhedonia has yet to be fully explored. Preliminary evidence
suggests that glutamate may have an integral role in both
anhedonia and depression.47,50 Ketamine is also a partial agonist
of the dopamine D2 receptor86,87 and has been found to increase
dopamine levels in the striatum, including the caudate and the
putamen.88 Intriguingly, Meyer et al.89 found that MDD patients
with co-occurring motor retardation symptoms exhibited lower
extracellular dopamine in the putamen compared with healthy
volunteers. Taken together, these ﬁndings suggest that the
glutamatergic system and its downstream modulation of dopa-
minergic activity may be one potential route of the anti-anhedonic
efﬁcacy of ketamine.
The present work has several limitations that should be noted.
First, the lack of a baseline PET image meant that we could not
exclude carryover effects in this crossover design. Second, the
experiential difference between receiving ketamine and saline can
be dramatic, and subjects likely realized what infusion they were
receiving in each session, potentially invalidating the placebo arm
of this study (however, see the recent article by Murrough et al.42).
Third, all participants continued to receive either lithium or
valproate, which may have masked or enhanced the effect of
ketamine. It is unknown whether the rapid-acting anti-anhedonic
effects of ketamine would also occur in unmedicated BD patients.
Finally, we do not know how applicable these ﬁndings may be to
MDD patients. Thus, we recommend that future studies attempt-
ing to replicate and extend the promising ﬁndings presented here
incorporate additional PET or functional imaging scans to evaluate
changes from baseline; study medication-free patients; and
examine both MDD and BD patients. Furthermore, exploring the
precise underlying reward processing improvements found here,
for example, via cognitive testing, is essential to our ability to
appropriately characterize the anti-anhedonic effects of ketamine.
Due to the prevalence of anhedonia in psychiatric and
neurological illnesses, particularly in schizophrenia, Parkinson’s
disease, drug addiction and both mood and anxiety disorders,
anhedonia has been suggested as a tractable endophenotype. As
outlined in the research domain criteria, identifying symptom-
based etiologies and their treatment may help to clarify speciﬁc
biological mechanisms mediating mental illnesses, aid to rectify
classiﬁcation and diagnostic issues currently inherent in psychiatry
and provide sustainable stepping stones toward treatment
improvements in mental health.
In sum, this study demonstrated that ketamine exerts rapid-
acting anti-anhedonic effects in treatment-refractory BD patients.
These anti-anhedonic effects remained even when the variance
associated with depression score changes was removed, suggest-
ing that ketamine ameliorates anhedonia independent of its
already considerable antidepressant effects. Furthermore, these
anti-anhedonic effects appeared to be mediated by increased
glucose metabolism in the dACC and putamen. Our results
underscore the putative utility of NMDA receptor antagonists to
treat all facets of depression.
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